AIM: Atherosclerotic renovascular disease (ARVD) may impair renal function and increase cardiovascular morbidity and mortality, but the mechanism by which ARVD impacts cardiovascular function is unclear. We tested the hypothesis that preservation of renal function can reverse cardiac dysfunction in ARVD. METHODS AND RESULTS: Endothelial progenitor cells (EPC) were injected intra-renally (ARVD+EPC) after 6 weeks of swine ARVD (concurrent hypercholesterolemia and renovascular hypertension), and single-kidney function and myocardial blood-flow and microvascular permeability (MP) responses to adenosine were assessed using CT 4 weeks later. Myocardial microvascular density was evaluated by micro-CT. Inflammation and oxidative-stress were assessed in kidney venous and systemic blood samples. Normal and untreated ARVD pigs served as controls. Blood pressure was similarly increased in ARVD and ARVD+EPC. Compared to normal, ARVD showed lower glomerular filtration rate, elevated renal vein and systemic oxidized LDL (ox-LDL), aldosterone, uric acid, isoprostanes, transforming growth factor (TGF)-β, and interleukine-6. Renal vein ox-LDL and TGF-β showed a positive gradient across the stenotic kidney, indicating increased renal oxidative stress and fibrogenic activity. Furthermore, ARVD impaired myocardial blood-flow and MP response to adenosine, decreased microvascular density, and induced myocardial fibrosis. Improvement of renal function in ARVD+EPC decreased systemic aldosterone, inflammation, and oxidative stress, and improved myocardial microvascular integrity and density. CONCLUSION: Selective improvement in renal function, which reduced renal and systemic oxidative stress and inflammation, preserved remote myocardial microvascular function and architecture, despite enduring hypertension. These findings underscore functionally important cardiorenal crosstalk possibly mediated by renal injury signals.
AIM: Atherosclerotic renovascular disease (ARVD) may impair renal function and increase cardiovascular morbidity and mortality, but the mechanism by which ARVD impacts cardiovascular function is unclear. We tested the hypothesis that preservation of renal function can reverse cardiac dysfunction in ARVD. METHODS AND RESULTS: Endothelial progenitor cells (EPC) were injected intra-renally (ARVD+EPC) after 6 weeks of swineARVD (concurrent hypercholesterolemia and renovascular hypertension), and single-kidney function and myocardial blood-flow and microvascular permeability (MP) responses to adenosine were assessed using CT 4 weeks later. Myocardial microvascular density was evaluated by micro-CT. Inflammation and oxidative-stress were assessed in kidney venous and systemic blood samples. Normal and untreated ARVDpigs served as controls. Blood pressure was similarly increased in ARVD and ARVD+EPC. Compared to normal, ARVD showed lower glomerular filtration rate, elevated renal vein and systemic oxidized LDL (ox-LDL), aldosterone, uric acid, isoprostanes, transforming growth factor (TGF)-β, and interleukine-6. Renal vein ox-LDL and TGF-β showed a positive gradient across the stenotic kidney, indicating increased renal oxidative stress and fibrogenic activity. Furthermore, ARVD impaired myocardial blood-flow and MP response to adenosine, decreased microvascular density, and induced myocardial fibrosis. Improvement of renal function in ARVD+EPC decreased systemic aldosterone, inflammation, and oxidative stress, and improved myocardial microvascular integrity and density. CONCLUSION: Selective improvement in renal function, which reduced renal and systemic oxidative stress and inflammation, preserved remote myocardial microvascular function and architecture, despite enduring hypertension. These findings underscore functionally important cardiorenal crosstalk possibly mediated by renal injury signals.
Authors: Ravinder K Wali; Gregory S Wang; Stephen S Gottlieb; Lavanya Bellumkonda; Riple Hansalia; Emilio Ramos; Cinthia Drachenberg; John Papadimitriou; Meredith A Brisco; Steve Blahut; Jeffrey C Fink; Michael L Fisher; Stephen T Bartlett; Matthew R Weir Journal: J Am Coll Cardiol Date: 2005-04-05 Impact factor: 24.094
Authors: Xiang-Yang Zhu; Martin Rodriguez-Porcel; Michael D Bentley; Alejandro R Chade; Vincenzo Sica; Claudio Napoli; Noel Caplice; Erik L Ritman; Amir Lerman; Lilach O Lerman Journal: Circulation Date: 2004-03-29 Impact factor: 29.690
Authors: Martin Rodriguez-Porcel; Joerg Herrman; Alejandro R Chade; James D Krier; Jerome F Breen; Amir Lerman; Lilach O Lerman Journal: Hypertension Date: 2004-01-12 Impact factor: 10.190
Authors: Lei Zhang; Xiang-Yang Zhu; Yu Zhao; Alfonso Eirin; Lei Liu; Christopher M Ferguson; Hui Tang; Amir Lerman; Lilach O Lerman Journal: Basic Res Cardiol Date: 2020-01-14 Impact factor: 17.165
Authors: Alfonso Eirin; John R Woollard; Christopher M Ferguson; Kyra L Jordan; Hui Tang; Stephen C Textor; Amir Lerman; Lilach O Lerman Journal: Transl Res Date: 2017-03-11 Impact factor: 7.012
Authors: Alfonso Eirin; Xiang-Yang Zhu; Behzad Ebrahimi; James D Krier; Scott M Riester; Andre J van Wijnen; Amir Lerman; Lilach O Lerman Journal: Cell Transplant Date: 2014-11-21 Impact factor: 4.064
Authors: Alfonso Eirin; Barbara J Williams; Behzad Ebrahimi; Xin Zhang; John A Crane; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: J Hypertens Date: 2014-01 Impact factor: 4.844
Authors: Alfonso Eirin; Behzad Ebrahimi; Xin Zhang; Xiang-Yang Zhu; Hui Tang; John A Crane; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Circ Cardiovasc Interv Date: 2012-10-09 Impact factor: 6.546
Authors: Kirandeep K Khangura; Alfonso Eirin; Garvan C Kane; Sanjay Misra; Stephen C Textor; Amir Lerman; Lilach O Lerman Journal: Am J Hypertens Date: 2013-10-25 Impact factor: 2.689